SEC Tracker
Get the app

Dyadic International DYAI

Dyadic International Q3 FY25: revenue $1.2M, down 41%; diluted EPS −$0.06

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Dyadic International reported for Q3 FY25, the quarter ended Sep 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.2M−41% from $2.0M in Q3 FY2410-Q income statement, on EDGAR
  2. Net income−$2.0MAgainst −$203K in Q3 FY2410-Q income statement, on EDGAR
  3. Diluted EPS−$0.06Against −$0.01 in Q3 FY2410-Q income statement, on EDGAR
  4. Cash and cash equivalents$5.8M−1% from $5.9M in Q3 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$1.9MAgainst −$201K in Q3 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Dyadic International files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Aytu Biopharma AYTU public float $24M, Dec 31, 2025
  2. Kala Bio KALA public float $25M, Jun 30, 2025
  3. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old
  4. Tenax Therapeutics TENX public float $24M, Jun 30, 2025
  5. Nanoviricides NNVC public float $24M, Dec 31, 2025